Nature1y
Cocaine addiction therapy—Are we partially there?
A recent study suggests that the dopamine D3 receptor partial agonist BP 897 prevents cocaine-seeking behavior in rats, and this may lead to new approaches to study and treat drug addiction.
CAPLYTA’s Strong Market Adoption Propels Its Rise as a Leading Antipsychotic Therapy | DelveInsight
Intra-Cellular Therapies’ CAPLYTA is making waves in the antipsychotic market, gaining traction as a novel treatment for schizophrenia and bipolar depression. With its differentiated safety profile ...
Nature6y
Picking out the pieces of GABA receptors
L-838,417 is a partial agonist at α2, α3 and α5 subunits and ... GABA A receptor modulators as a potential new class of drugs for chronic pain.
Monthly Prescribing Reference1y
Codeine Sulfate
Drug abusers. Elderly ... nalbuphine, pentazocine) or partial agonist (eg, buprenorphine); may reduce effects and/or precipitate withdrawal symptoms. Potentiated by CYP3A4 inhibitors (eg ...
Hosted on MSN2mon
AbbVie’s Phase III trial of Parkinson’s disease treatment meets primary endpoint
Following these results, AbbVie aims to submit a new drug application (NDA ... potential of tavapadon as a first-in-class D1/D5 partial agonist for the treatment of Parkinson's disease.
Monthly Prescribing Reference7mon
Fentanyl Citrate Injection
Drug abusers. Renal or hepatic impairment ... nalbuphine, pentazocine) or partial agonist (eg, buprenorphine); may reduce effects and/or precipitate withdrawal symptoms. Potentiated by CYP3A4 ...
Vigil says FDA removed partial hold on Alzheimer’s candidate
Vigil Neuroscience (NASDAQ:VIGL) announced Tuesday that the U.S. Food and Drug Administration (FDA) has removed the partial ...
Neurology Advisor22d
Labeling for ADHD Med Qelbree Updated With Lactation, Pharmacodynamic Data
The updated labeling for Qelbree provides additional information on the pharmacodynamic profile of the drug. Findings show that viloxazine binds to and exhibits partial agonist activity at the ...